Monday, September 26, 2016 7:38:31 AM
Source: PR Newswire (US)
CUPERTINO, Calif., Sept. 26, 2016 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Pain Therapeutics' New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII. Based on its review, the FDA has determined that the NDA cannot be approved in its present form and specifies additional actions and data that are needed for drug approval.
In a press release issued this morning by Pain Therapeutics, Pain Therapeutics states that "The CRL focuses on the abuse-deterrent properties of REMOXY ER and proposed drug labeling. The CRL makes no mention of clinical safety, drug efficacy, manufacturing, stability, bioequivalence or any other issues from a prior Complete Response Letter."
The announcement continues that "Pain Therapeutics is evaluating the CRL and plan further discussions with the FDA. The CRL specifies additional actions that are needed in order to obtain approval of REMOXY ER with label claims against three routes of abuse (i.e., injection, inhalation and snorting). These actions may take approximately a year to conduct and may cost approximately $5MM, pending discussions with the FDA and outside clinical/regulatory consultants."
In addition, the Pain Therapeutics provides the following details of the Complete Response Letter (CRL):
"The CRL focuses on the actions and studies that are needed in order to obtain approval of REMOXY ER with label claims on three routes of abuse (i.e., injection, inhalation and snorting). In conducting the following studies, we will generally compare REMOXY ER vs. one or more commercially available oxycodone ER drug product:
To support a potential drug label claim against abuse by injection: Repeat an injectability/syringeability study using thin films of drug, smaller volumes of solvents, additional mixed solvents and alternative extraction methods and syringe filter.
To support a potential drug label claim against abuse by inhalation: Repeat a volatilization study using the same thickness for each drug to increase surface area.
To support a potential drug label claim against abuse by snorting: Conduct an intranasal abuse potential study in human volunteers (i.e., not the animal data we had submitted) with drug applied directly inside the human nasal cavity.
In addition, we had proposed in the REMOXY NDA a label claim against abuse by chewing. Our proposal was based on clinical results of an oral human abuse potential study that met all four co-primary endpoints with statistical significance and that also met several, but not all, secondary endpoints. The CRL asks us to submit a revised proposed label to indicate results of this study do not support a label claim against abuse by chewing."
In December 2002, DURECT licensed to Pain Therapeutics the exclusive right to develop and commercialize on a worldwide basis REMOXY ER and other specified opioid analgesics utilizing DURECT's ORADUR extended-release, abuse-deterrent technology. Under the terms of that license, Pain Therapeutics funds the development program including reimbursing DURECT for formulation and other work performed for Pain Therapeutics. DURECT may also receive additional payments if certain development and regulatory milestones are achieved. DURECT is eligible to also receive royalties of between 6.0% to 11.5% of net sales if REMOXY ER is commercialized, and may receive additional income from the sale of key excipients supplied by DURECT for use in the manufacture of REMOXY ER.
About DURECT Corporation
DURECT is a biopharmaceutical company focused on two areas of active drug development: new therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its Epigenomic Regulator Program. DURECT's current focus is on pain management, CNS disorders, acute organ injury, and metabolic diseases such as NAFLD/NASH. Late stage development programs utilizing DURECT's drug delivery technologies include POSIMIR® (SABER®-Bupivacaine) and REMOXY® ER (oxycodone) extended-release capsules CII. DURECT's Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival. For more information, please visit www.durect.com.
DURECT Forward-Looking Statement
The statements in this press release regarding REMOXY ER, its potential attributes including its potential uses and features, Pain Therapeutics' on-going review by and interactions with FDA regarding approval of the REMOXY ER NDA, potential additional studies that Pain Therapeutics may conduct, the potential of resolving all outstanding regulatory concerns regarding REMOXY ER and the amount of time it will take to do so, and potential payments under DURECT's agreement with Pain Therapeutics are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Pain Therapeutics may not be able to adequately address all of FDA's concerns regarding the REMOXY ER NDA or there could be a delay in addressing such concerns, the potential that FDA may not grant regulatory approval of REMOXY ER, further delays and additional costs due to requirements imposed by the FDA, the risk that Pain Therapeutics may terminate plans to develop and commercialize REMOXY ER,the risks of obtaining marketplace acceptance of REMOXY, developments of products or technologies by current or future competitors, avoiding infringing patents held by other parties and securing and defending patents related to REMOXY. Further information regarding these and other risks is included under the heading "Risk Factors" in DURECT's Form 10-Q dated August 2, 2016 filed with the Securities and Exchange Commission.
NOTE: POSIMIR®, ORADUR® and SABER® are trademarks of DURECT Corporation. REMOXY ER, POSIMIR and DUR-928 are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/durects-licensee-pain-therapeutics-receives-complete-response-letter-from-fda-for-remoxy-er-oxycodone-extended-release-capsules-cii-300333771.html
SOURCE DURECT Corporation
Copyright 2016 PR Newswire
Recent DRRX News
- DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis • PR Newswire (US) • 04/30/2024 11:00:00 AM
- DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 03/27/2024 08:01:00 PM
- DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 03/20/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 04:37:57 PM
- DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada • PR Newswire (US) • 03/04/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:16:39 PM
- DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 11:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:15:11 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 12/01/2023 09:28:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:18 PM
- DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update • PR Newswire (US) • 11/13/2023 09:05:00 PM
- DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 11/09/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:10:15 PM
- DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality • PR Newswire (US) • 11/07/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 01:02:52 PM
- DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis • PR Newswire (US) • 09/07/2023 11:00:00 AM
- DURECT Corporation Announces Presentations in Upcoming Investor Conferences • PR Newswire (US) • 08/31/2023 08:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/10/2023 08:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:18:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:23:04 PM
- DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update • PR Newswire (US) • 08/09/2023 08:05:00 PM
- DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 08/03/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 09:13:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/21/2023 02:38:08 PM
- DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 07/20/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM